Roger Frechette, PhD
Roger is a life-sciences entrepreneur and consultant with over 22 years experience in drug discovery research and early drug development. He is a partner and co-founder of New England PharmAssociates, LLC.
In 2004, he co-founded MaxThera, Inc., a drug discovery research company developing novel antibacterial agents to treat life-threatening infections caused by antibiotic resistant pathogens. He served as VP of Chemistry and R&D Operations for MaxThera. The company was formed through the acquisition of the drug discovery portfolio developed at Genome Therapeutics Corporation, where Roger was a medicinal chemistry consultant. MaxThera was funded by the US Bioshield Program and by SBIR grants administered through the NIAID (NIH). MaxThera’s antibacterial assets were sold in early 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company.
Prior to starting MaxThera, Roger was a independent drug discovery and life-sciences consultant following his role as Project Director at Paratek Pharmaceuticals, in Boston, where he had successfully led the team that discovered PTK0796, and oversaw the pre-clinical development program. PTK0796 is a novel antibacterial agent currently in Phase III clinical trials. Prior to Paratek, he was Associate Director of chemistry at RiboGene, Inc, in Hayward, CA, where he built the chemistry department and managed two drug discovery programs in collaboration with a Japanese strategic partner. He began his career as a medicinal chemist at the R.W. Johnson Pharmaceutical Research Institute (A Johnson and Johnson Company) in Raritan, NJ.Follow @rofrechette